| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | YRDC |
| Uniprot No | Q86U90 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-270 aa |
| 活性数据 | MRAAVAASVGLSEGPAGSRSGRLFRPPSPAPAAPGARLLRLPGSGAVQAASPERAGWTEALRAAVAELRAGAVVAVPTDTLYGLACAASCSAALRAVYRLKGRSEAKPLAVCLGRVADVYRYCRVRVPEGLLKDLLPGPVTLVMERSEELNKDLNPFTPLVGIRIPDHAFMQDLAQMFEGPLALTSANLSSQASSLNVEEFQDLWPQLSLVIDGGQIGDGQSPECRLGSTVVDLSVPGKFGIIRPGCALESTTAILQQKYGLLPSHASYL |
| 分子量 | 54.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于重组人YRDC蛋白的示例参考文献(注：以下为虚拟示例，非真实文献)：
---
1. **《Expression and purification of recombinant human YRDC protein in Escherichia coli》**
作者：Li X et al.
摘要：本研究成功构建了在大肠杆菌系统中高效表达人YRDC蛋白的重组质粒，并通过镍柱亲和层析获得高纯度蛋白，为后续功能研究奠定基础。
2. **《Structural insights into the catalytic mechanism of human YRDC in tRNA modification》**
作者：Wang Y et al.
摘要：通过X射线晶体学解析了重组人YRDC蛋白的3D结构，揭示了其参与tRNA硫修饰的活性位点和催化机制，提示其在翻译调控中的关键作用。
3. **《YRDC knockdown disrupts redox homeostasis and induces apoptosis in cancer cells》**
作者：Chen J et al.
摘要：利用重组YRDC蛋白进行功能验证实验，发现其缺失会导致癌细胞氧化应激水平升高并触发线粒体凋亡通路，表明其在癌症中的潜在治疗靶点价值。
4. **《A CRISPR-Cas9 screen identifies YRDC as a regulator of genome stability》**
作者：Smith TL et al.
摘要：通过基因编辑技术结合重组YRDC蛋白回补实验，证明该蛋白通过与DNA修复酶相互作用维持基因组稳定性，突变体可导致染色体断裂频率增加。
---
提示：实际文献需通过PubMed、Web of Science等数据库检索确认。研究关键词建议：YRDC (Yeast-Related Dicysteine)、tRNA modification、氧化应激、酶催化机制。
YRDC (YrdC domain-containing protein) is a conserved eukaryotic protein involved in post-transcriptional modification of transfer RNA (tRNA). In humans, YRDC plays a critical role in the biosynthesis of wybutosine (yW), a hypermodified guanine derivative found at position 37 of phenylalanine tRNA (tRNA^Phe). This modification is essential for maintaining translational fidelity by stabilizing tRNA-mRNA interactions and preventing frameshift errors during protein synthesis. Structurally, YRDC contains a radical S-adenosylmethionine (SAM) domain and a C-terminal YrdC/Sui1 homology region, both implicated in its enzymatic activity.
Recombinant human YRDC protein is produced through genetic engineering techniques, typically expressed in bacterial or mammalian systems for biochemical and functional studies. Its recombinant form enables researchers to investigate molecular mechanisms underlying tRNA modification, defects in which have been linked to developmental disorders and diseases. Studies using recombinant YRDC have revealed its collaboration with other enzymes, such as TYW1 and TYW3. in the multi-step wybutosine synthesis pathway. Additionally, YRDC's potential connections to cellular stress responses and cancer biology have spurred interest in its regulatory roles beyond tRNA modification. As an evolutionarily ancient protein, YRDC also serves as a model for studying conserved translational quality control mechanisms across species.
×
